Omnicell Inc

Omnicell Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.0, indicating no reported interest-bearing debt relative to equity. The company holds $196.52 million in cash and equivalents against total liabilities of $742.91 million, resulting in a low liquidity risk assessment. Total equity stands at $1.23 billion, providing a substantial buffer against liabilities. Operating cash flow of $127.30 million supports the balance sheet, while capital expenditures of $40.42 million suggest moderate reinvestment in assets.

Profitability metrics indicate thin returns on capital, with a return on equity of 1.66% and a return on assets of 1.03%. Operating income is minimal at $5.16 million against gross profit of $503.44 million, suggesting high operating expenses relative to gross margins. Net income of $2.05 million reflects the bottom-line impact of these costs. Without cohort median data for direct comparison, these returns appear low for a health care equipment company, which typically commands higher margins.

Revenue concentration and geographic exposure details are not provided in the available data, preventing an analysis of segment mix or regional risk. The company’s total revenue is $1.18 billion, but the breakdown by product line or geography is absent from the current snapshot.

Growth trajectory cannot be assessed due to the absence of historical period data for revenue or net income trends. The current financial snapshot provides a single-period view, lacking the multi-year context necessary to determine growth momentum or cyclicality.

Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The basic and diluted shares outstanding are identical at 45.03 million, confirming no current dilution from options or convertible securities. The primary risk appears to be operational, given the low operating income relative to revenue.

Recent analyst sentiment is moderately positive, with a mean recommendation of 2.00 (buy) and a mean price target of $61.29. The consensus includes one strong buy, six buys, and one hold, with price targets ranging from $55.00 to $70.00. No specific news events, filing observations, or transcript insights are available to contextualize recent market movements.

Analysts project 30.9% upside to a mean price target of $61.29, reflecting strong buy consensus among eight analysts.

Cash conversion of 6.23 ranks best-in-class within the insurance cohort, significantly outperforming the median of 1.47.

Operating income surged 1,431.2% year-over-year to $5.16 million, demonstrating a sharp recovery in core profitability.

Long-term debt decreased substantially to $167.6 million in FY2026, indicating aggressive deleveraging and improved balance sheet health.

The company maintains a low leverage band with a debt-to-equity ratio of 0.60, suggesting manageable financial risk.

Revenue growth remains sluggish with a four-year CAGR of only 1.1%, indicating limited top-line expansion potential.

Revenue $309.9M, +14,9% YoY; Operating income +245,1% YoY.

• ▍Revenue $309.9M, +14,9% YoY
• ▍Operating income +245,1% YoY
• ▍Net income +261,7% YoY
• ▍Free cash flow +628,3% YoY
• ▍Net margin 3.7%

Revenue $314.0M, +2,3% YoY; Operating income −96,7% YoY.

• ▍Revenue $314.0M, +2,3% YoY
• ▍Operating income −96,7% YoY
• ▍Net income −112,8% YoY
• ▍Free cash flow −84,9% YoY
• ▍Net margin -0.6%

Revenue $310.6M, +10,0% YoY; Operating income +25,6% YoY.

• ▍Revenue $310.6M, +10,0% YoY
• ▍Operating income +25,6% YoY
• ▍Net income −36,7% YoY
• ▍Free cash flow −31,7% YoY
• ▍Net margin 1.8%

Revenue $290.6M, +5,0% YoY; Operating income +151,9% YoY.

• ▍Revenue $290.6M, +5,0% YoY
• ▍Operating income +151,9% YoY
• ▍Net income +51,0% YoY
• ▍Free cash flow −7,3% YoY
• ▍Net margin 1.9%

Revenue $269.7M; Operating income -$11.6M.

• ▍Revenue $269.7M
• ▍Operating income -$11.6M
• ▍Net margin -2.6%

Revenue $306.9M; Operating income $12.4M.

• ▍Revenue $306.9M
• ▍Operating income $12.4M
• ▍Net margin 5.2%

Revenue $282.4M; Operating income $6.6M.

• ▍Revenue $282.4M
• ▍Operating income $6.6M
• ▍Net margin 3.1%

Revenue $276.8M; Operating income $3.2M.

• ▍Revenue $276.8M
• ▍Operating income $3.2M
• ▍Net margin 1.3%

Revenue $1.18B, +6,5% YoY; Operating income +1 431,2% YoY.

• ▍Revenue $1.18B, +6,5% YoY
• ▍Operating income +1 431,2% YoY
• ▍Net income −83,6% YoY
• ▍Free cash flow −61,8% YoY
• ▍Net margin 0.2%

Revenue $1.11B, −3,0% YoY; Operating income +101,0% YoY.

• ▍Revenue $1.11B, −3,0% YoY
• ▍Operating income +101,0% YoY
• ▍Net income +161,5% YoY
• ▍Free cash flow +349,5% YoY
• ▍Net margin 1.1%

Revenue $1.15B, −11,5% YoY; Operating income −1 401,0% YoY.

• ▍Revenue $1.15B, −11,5% YoY
• ▍Operating income −1 401,0% YoY
• ▍Net income −460,7% YoY
• ▍Free cash flow −62,6% YoY
• ▍Net margin -1.8%

Revenue $1.30B, +14,5% YoY; Operating income −102,6% YoY.

• ▍Revenue $1.30B, +14,5% YoY
• ▍Operating income −102,6% YoY
• ▍Net income −92,7% YoY
• ▍Free cash flow −65,5% YoY
• ▍Net margin 0.4%